PharmaPROP.BXL
De berekende faillissementskans van PharmaPROP.BXL over 12 maanden bedraagt 8,1% (verhoogd). De jaarrekening over 2024 toont een negatief eigen vermogen (€-1k) en een nettoresultaat van €-2k. Het bedrijf is actief sinds 2023 en het Belgisch Staatsblad bevat geen insolventie- of waarschuwingssignalen.
| Eigen vermogen | €-1k |
| Netto resultaat | €-2k |
| Actief | 2 jaar |
| Vestigingen | 1 |
Gemengd profiel: sterk in rentabiliteit, zwakker in gezondheid.
Statistische inschatting op basis van openbare bronnen, geen kredietadvies of vaststelling. Hoe berekenen we dit?
De volledige opbouw van de score, de scoregeschiedenis per boekjaar en de indicatieve kredietlimiet ontgrendel je met Plus.
Bekijk plannen →| Boekjaar | 2024 |
|---|---|
| Omzet | - |
| EBITDA | €46k |
| Nettoresultaat | €-2k |
| Cashflow | €29k |
| Personeelskosten | - |
| Belastingen op het resultaat | - |
| Dividenden | - |
| Totaal activa | €883k |
| Eigen vermogen | €-1k |
| Schulden | €884k |
| waarvan ≤ 1 jaar | €236k |
| waarvan > 1 jaar | €642k |
| Werkkapitaal | €-205k |
| Werknemers (VTE) | 0,0 |
| 2024 | |
|---|---|
| Current ratio | 0,13 |
| Quick ratio | 0,13 |
| Werkkapitaalratio | -23,2% |
| Solvabiliteit | -0,1% |
| Debt / equity | -760,27 |
| Langetermijnschuldgraad | -552,13 |
| Interest coverage | 2,71 |
| Bruto rentabiliteit | - |
| Netto rentabiliteit | - |
| ROA | -0,2% |
| ROE | 186,0% |
| EBITDA-marge | - |
| Klantenkrediet (DSO) | - |
| Leverancierskrediet (DPO) | - |
| Voorraadrotatie | - |
| Voorraaddagen (DSI) | - |
| Post | Code | 2024 |
|---|---|---|
| Balans, Activa | ||
| TOTAAL ACTIVA | 20/58 | €883k |
| Vaste activa | 21/28 | €852k |
| Materiële vaste activa | 22/27 | €852k |
| Vlottende activa | 29/58 | €31k |
| Vorderingen op ten hoogste één jaar | 40/41 | €24k |
| Liquide middelen | 54/58 | €8k |
| Balans, Passiva | ||
| TOTAAL PASSIVA | 10/49 | €883k |
| Eigen vermogen | 10/15 | €-1k |
| Inbreng / kapitaal | 10/11 | €1k |
| Overgedragen winst (verlies) | 14 | €-2k |
| Schulden | 17/49 | €884k |
| Schulden op meer dan één jaar | 17 | €642k |
| Schulden op ten hoogste één jaar | 42/48 | €236k |
| Handelsschulden op ten hoogste één jaar | 44 | €406 |
| Resultatenrekening | ||
| Bruto bedrijfsmarge | 9900 | €50k |
| Bedrijfsresultaat | 9901 | €15k |
| Financiële kosten | 65 | €17k |
| Resultaat vóór belasting | 9903 | €-2k |
| Resultaat van het boekjaar | 9904 | €-2k |
| Te bestemmen resultaat | 9905 | €-2k |
| NACE primair | - |
| Rechtsvorm | BV(610) |
| Oprichtingsdatum | 08-08-2023 |
| Status | Actief |
| Postcode | 1000 |
Percelen gekoppeld aan dit bedrijf via zijn adressen in de KBO (zetel, vestigingen, bijkantoren), gekruist met het kadastraal percelenplan. Dit toont waar het bedrijf actief is, geen eigendomsregister.
| Perceel (capakey) | Regio | Oppervlakte | Gebouwen | Hoogte / verd. |
|---|---|---|---|---|
| 21803C0405/00H000 | Brussel | 211 m² | 1 · 172 m² | 22,4 m · 6 verd. |
Eén tijdlijn van alles wat er met dit bedrijf is gebeurd, publicaties, insolventie- en levensloopgebeurtenissen, administratieve wijzigingen en neergelegde jaarrekeningen.
13-04-2026 Act object · General meeting · Permanent representative · Officer resignation
- Filing: 2026-04-03 · PharmaPROP.BXL
- Publication: 2026-04-13 · PharmaPROP.BXL
- Act object: Constatation changement représentant permanent · PharmaPROP.BXL
- General meeting: 2026-02-13 · PharmaPROP.BXL
- Permanent representative: role: représentant permanent, context: représentation de la société-administrateur PharmaBXL au sein de PharmaPROP.BXL, start_date: 2025-12-12 · Georges DE FEU
- Officer resignation: role: représentant permanent, context: remplacement par Georges DE FEU, end_date: 2025-12-12 · Olivier OLBRECHTS
- Approval: meeting_date: 2026-02-13, decision_date: 2025-12-12, approving_body: organe d'administration de la SRL PharmaBXL, approved_by_meeting: assemblée générale spéciale de PharmaPROP.BXL · PharmaPROP.BXL
Technische details
{
"facts": [
{
"type": "filing",
"quote": "D\u00E9pos\u00E9 / Re\u00E7u le U 3 AVR. 2026",
"value": "2026-04-03",
"object": null,
"subject": "e1"
},
{
"type": "publication",
"quote": "Bijlagen bij het Belgisch Staatsblad - 13/04/2026",
"value": "2026-04-13",
"object": null,
"subject": "e1"
},
{
"type": "act_object",
"quote": "Objet de l\u0027acte: Constatation changement repr\u00E9sentant permanent",
"value": "Constatation changement repr\u00E9sentant permanent",
"object": null,
"subject": "e1"
},
{
"type": "general_meeting",
"quote": "Extrait du proc\u00E8s-verbal de l\u0027assembl\u00E9e g\u00E9n\u00E9rale sp\u00E9ciale tenue le 13/02/2026",
"value": "2026-02-13",
"object": null,
"subject": "e1"
},
{
"type": "permanent_representative",
"quote": "L\u0027assembl\u00E9e constate que la soci\u00E9t\u00E9-administrateur, SRL \u00AB PharmaBXL \u003E (num\u00E9ro d\u0027entreprise 0795.508.480), est repr\u00E9sent\u00E9e par Monsieur Georges DE FEU en qualit\u00E9 de repr\u00E9sentant permanent, \u00E0 compter du 12/12/2025",
"value": {
"role": "repr\u00E9sentant permanent",
"context": "repr\u00E9sentation de la soci\u00E9t\u00E9-administrateur PharmaBXL au sein de PharmaPROP.BXL",
"start_date": "2025-12-12"
},
"object": "e2",
"subject": "e3"
},
{
"type": "officer_resignation",
"quote": "et non plus par Monsieur Olivier OLBRECHTS.",
"value": {
"role": "repr\u00E9sentant permanent",
"context": "remplacement par Georges DE FEU",
"end_date": "2025-12-12"
},
"object": "e2",
"subject": "e4"
},
{
"type": "approval",
"quote": "L\u0027assembl\u00E9e prend acte de la d\u00E9cision prise le 12/12/2025 par l\u0027organe d\u0027administration de la SRL \u003C\u003C PharmaBXL \u00BB (num\u00E9ro d\u0027entreprise 0795.508.480), qui est soci\u00E9t\u00E9-administrateur de notre soci\u00E9t\u00E9.",
"value": {
"meeting_date": "2026-02-13",
"decision_date": "2025-12-12",
"approving_body": "organe d\u0027administration de la SRL PharmaBXL",
"approved_by_meeting": "assembl\u00E9e g\u00E9n\u00E9rale sp\u00E9ciale de PharmaPROP.BXL"
},
"object": "e2",
"subject": "e1"
}
],
"act_meta": {
"model_id": 40,
"extractor": "open-capture-27b-v3",
"ocr_chars": 1529,
"truncated": false,
"needs_verify": false
},
"entities": [
{
"id": "e1",
"kbo": "0804.643.803",
"kind": "company",
"name": "PharmaPROP.BXL",
"attrs": {
"address": "Avenue Albert 154, 1190 Forest",
"legal_form": "Soci\u00E9t\u00E9 \u00E0 responsabilit\u00E9 limit\u00E9e"
}
},
{
"id": "e2",
"kbo": "0795.508.480",
"kind": "company",
"name": "PharmaBXL",
"attrs": {
"role": "soci\u00E9t\u00E9-administrateur",
"legal_form": "Soci\u00E9t\u00E9 \u00E0 responsabilit\u00E9 limit\u00E9e"
}
},
{
"id": "e3",
"kbo": null,
"kind": "person",
"name": "Georges DE FEU",
"attrs": {
"role": "repr\u00E9sentant permanent"
}
},
{
"id": "e4",
"kbo": null,
"kind": "person",
"name": "Olivier OLBRECHTS",
"attrs": {
"role": "ancien repr\u00E9sentant permanent"
}
}
]
}10-08-2023 Oprichting van een SRL
Technische details
{
"kind": "oprichting",
"seat": "1190 Forest, Avenue Albert 154",
"schema": "v3.2",
"act_meta": {
"model_id": 36,
"extractor": "constrained-core-35b"
},
"founders": [
{
"org": {
"kbo": null,
"name": "PHARMABXL"
},
"kind": "rechtspersoon",
"person": null,
"share_class": "A",
"partner_role": null,
"holder_org_kbo": null,
"holder_org_name": "PHARMABXL",
"contribution_type": "cash",
"amount_paid_in_eur": 900,
"holder_person_name": null,
"is_subscriber_only": false,
"n_shares_subscribed": 900000,
"amount_subscribed_eur": 900,
"is_anonymous_silent_partner": false
},
{
"org": {
"kbo": null,
"name": "FILIP GILIAS"
},
"kind": "rechtspersoon",
"person": null,
"share_class": "B",
"partner_role": null,
"holder_org_kbo": null,
"holder_org_name": "FILIP GILIAS",
"contribution_type": "cash",
"amount_paid_in_eur": 122.96,
"holder_person_name": null,
"is_subscriber_only": true,
"n_shares_subscribed": 12296,
"amount_subscribed_eur": 122.96,
"is_anonymous_silent_partner": false
},
{
"org": {
"kbo": null,
"name": "REMEDIA"
},
"kind": "rechtspersoon",
"person": null,
"share_class": "B",
"partner_role": null,
"holder_org_kbo": null,
"holder_org_name": "REMEDIA",
"contribution_type": "cash",
"amount_paid_in_eur": 134.89,
"holder_person_name": null,
"is_subscriber_only": true,
"n_shares_subscribed": 13489,
"amount_subscribed_eur": 134.89,
"is_anonymous_silent_partner": false
},
{
"org": {
"kbo": null,
"name": "PHARMALEGAL"
},
"kind": "rechtspersoon",
"person": null,
"share_class": "B",
"partner_role": null,
"holder_org_kbo": null,
"holder_org_name": "PHARMALEGAL",
"contribution_type": "cash",
"amount_paid_in_eur": 496.23,
"holder_person_name": null,
"is_subscriber_only": true,
"n_shares_subscribed": 49623,
"amount_subscribed_eur": 496.23,
"is_anonymous_silent_partner": false
},
{
"org": {
"kbo": null,
"name": "O2C"
},
"kind": "rechtspersoon",
"person": null,
"share_class": "B",
"partner_role": null,
"holder_org_kbo": null,
"holder_org_name": "O2C",
"contribution_type": "cash",
"amount_paid_in_eur": 245.92,
"holder_person_name": null,
"is_subscriber_only": true,
"n_shares_subscribed": 24592,
"amount_subscribed_eur": 245.92,
"is_anonymous_silent_partner": false
}
],
"capital_eur": 1000,
"subject_company": {
"kbo": "0804.643.803",
"name_full": "PharmaPROP.BXL",
"legal_form": "SRL"
},
"initial_directors": [],
"incorporation_date": "2023-08-07",
"post_incorporation_mandates": []
}Genereer een gestructureerde, feitelijke nota op basis van alle signalen in dit dossier: risico, financiële gezondheid, eigendomsstructuur, mandaten en sectorvergelijking.
| Officiële naamFR | PharmaPROP.BXL |